When #myeloma patients have access to CAR-T, OS may not be improved by giving it earlier. However, line 5 is too late. For pts diagnosed late 2010s and after, triple-class refractoriness is often seen after 2L. 4.4mo med PFS for control arm in KarMMa-3 is sobering. #mmsm

I love this figure from a recent review of high risk MM by Matthew Rees and Shaji Kumar in AmericanJournalofHematology. Risk is a spectrum that involves so much more than cytogenetics and ISS stage! #mmsm onlinelibrary.wiley.com/doi/full/10.10…

I'm a little awestruck at the sight of my fellowship research project hitting the 100 citation mark! What an amazing and timely project that was designed for me by Jonathan Kaufman, MD, Larry Boise, and Winship Cancer Institute of Emory University myeloma group. Couldn't have done it without such great mentors!

Congrats to Ben Derman et al on this important study of extended DaraKRd for patients with newly-diagnosed myeloma. Please read my commentary (with table of outcomes from all known CD38/KRd trials), available here: rdcu.be/dJTR0 Blood Cancer Journal #mmsm #mmMRD

Does any data exist about the impact of venetoclax on autologous stem cell mobilization? Maybe somewhere in the lymphoma literature? #mmsm #bmtsm

Coming soon! Episode on newly diagnosed transplant-ineligible #MultipleMyeloma & in-depth analysis of 𝐈𝐌𝐑𝐎𝐙 and 𝐈𝐅𝐌-𝟐𝟎𝟐𝟎/𝐁𝐄𝐍𝐄𝐅𝐈𝐓 trials with Timothy Schmidt, MD! #EHA24 #ASCO24 #mmsm

Perhaps the best figure I've found supporting the use of Dara+Len maintenance after ASCT among those receiving DaraVRd. Even among MRD- patients, PFS looks better for DR vs R. Still not sure it's worth adding for everyone, but I'm more supportive of it. rdcu.be/dPFo2

Semantics question - how to define CAR-T toxicity duration? For example, if someone has Gr2 CRS, gets toci/dex x1 +/- acetaminophen, fever resolves promptly after toci/dex, at what point do we say it's "resolved"? Related Q (no poll) - defining ongoing vs recurrent CRS?

Dr. Sandra Susanibar-Adaniya from Penn Medicine reviews how to treat myeloma after progression on BCMA CAR-T therapy. Beyond Trauma Foundation #mmsm

Great discussions about updates in DLBCL, MCL, and HL by P. Venugopal Christopher D'Angelo Christopher Fletcher at the WI myeloma/lymphoma summit Beyond Trauma Foundation #lymsm

Tune in to our new episode on quadruplets in newly diagnosed transplant-ineligible #Myeloma with Timothy Schmidt, MD! 🎙️ We break down the IMROZ & BENEFIT trials and how to apply them in our current practice. 🩺🔍 share.transistor.fm/s/6e20d230 Check out this short clip!

How do you approach patients with AL amyloidosis with high plasmacytosis in the bone marrow (ex. 35%) but no other evidence of myeloma?

#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/39965175/. #mmsm

Cartitude-1 LTFU data is very exciting. Unprecedented results! But I think we need to be extremely cautious calling this a cure or functional cure. For me, cure in MM is when I can look a patient in their eyes and tell them they don't need to return to clinic. Not there yet.

It was a pleasure to review the CIBMTR analysis of ide-cel for Blood Journals Portfolio and for the invitation to write a commentary. Great data generated by Surbhi Sidana, MD et al confirming the safety and efficacy of ide-cel for myeloma in a real world setting. authors.elsevier.com/a/1lPab1UYwr0b7

Real-world data provide a CARbon copy for ide-cel #mmsm #bmtsm Timothy Schmidt, MD Blood Journals Portfolio ashpublications.org/blood/article/…